Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.

Nabergoj S, Mlinarič-Raščan I, Jakopin Ž.

Med Res Rev. 2018 Dec 13. doi: 10.1002/med.21557. [Epub ahead of print] Review.

PMID:
30548868
2.

Medicines associated with folate-homocysteine-methionine pathway disruption.

Vidmar M, Grželj J, Mlinarič-Raščan I, Geršak K, Dolenc MS.

Arch Toxicol. 2019 Feb;93(2):227-251. doi: 10.1007/s00204-018-2364-z. Epub 2018 Nov 29. Review.

PMID:
30499019
3.

Novel motif of variable number of tandem repeats in TPMT promoter region and evolutionary association of variable number of tandem repeats with TPMT*3 alleles.

Urbančič D, Šmid A, Stocco G, Decorti G, Mlinarič-Raščan I, Karas Kuželički N.

Pharmacogenomics. 2018 Nov;19(17):1311-1322. doi: 10.2217/pgs-2018-0123. Epub 2018 Oct 22.

4.

Common polymorphism in the glycine N-methyltransferase gene as a novel risk factor for cleft lip with or without cleft palate.

Karas Kuželički N, Šmid A, Kek T, Eberlinc A, Geršak K, Mlinarič-Raščan I.

Int J Oral Maxillofac Surg. 2018 Nov;47(11):1381-1388. doi: 10.1016/j.ijom.2018.06.001. Epub 2018 Jun 30.

PMID:
30318092
5.

Methylation of selenocysteine catalysed by thiopurine S-methyltransferase.

Urbančič D, Kotar A, Šmid A, Jukič M, Gobec S, Mårtensson LG, Plavec J, Mlinarič-Raščan I.

Biochim Biophys Acta Gen Subj. 2019 Jan;1863(1):182-190. doi: 10.1016/j.bbagen.2018.10.002. Epub 2018 Oct 9.

6.

Endocrine disrupting activities and immunomodulatory effects in lymphoblastoid cell lines of diclofenac, 4-hydroxydiclofenac and paracetamol.

Klopčič I, Markovič T, Mlinarič-Raščan I, Sollner Dolenc M.

Toxicol Lett. 2018 Sep 15;294:95-104. doi: 10.1016/j.toxlet.2018.05.022. Epub 2018 May 16.

PMID:
29777833
7.

Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.

Gobec M, Tomašič T, Štimac A, Frkanec R, Trontelj J, Anderluh M, Mlinarič-Raščan I, Jakopin Ž.

J Med Chem. 2018 Apr 12;61(7):2707-2724. doi: 10.1021/acs.jmedchem.7b01052. Epub 2018 Mar 22.

PMID:
29543461
8.

Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine.

Valencic E, Smid A, Jakopin Z, Tommasini A, Mlinaric-Rascan I.

Curr Med Chem. 2018;25(24):2764-2782. doi: 10.2174/0929867324666170830101215. Review.

PMID:
28875839
9.

Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies.

Tamm R, Mägi R, Tremmel R, Winter S, Mihailov E, Smid A, Möricke A, Klein K, Schrappe M, Stanulla M, Houlston R, Weinshilboum R, Mlinarič Raščan I, Metspalu A, Milani L, Schwab M, Schaeffeler E.

Clin Pharmacol Ther. 2017 May;101(5):684-695. doi: 10.1002/cpt.540. Epub 2017 Feb 1. Review.

10.

Identification of indole scaffold-based dual inhibitors of NOD1 and NOD2.

Keček Plešec K, Urbančič D, Gobec M, Pekošak A, Tomašič T, Anderluh M, Mlinarič-Raščan I, Jakopin Ž.

Bioorg Med Chem. 2016 Nov 1;24(21):5221-5234. doi: 10.1016/j.bmc.2016.08.044. Epub 2016 Aug 24.

PMID:
27601373
11.

Structural features of subtype-selective EP receptor modulators.

Markovič T, Jakopin Ž, Dolenc MS, Mlinarič-Raščan I.

Drug Discov Today. 2017 Jan;22(1):57-71. doi: 10.1016/j.drudis.2016.08.003. Epub 2016 Aug 6. Review.

12.
13.

Risk factors for symptomatic osteonecrosis in childhood ALL: A retrospective study of a Slovenian pediatric ALL population between 1970 and 2004.

Karas-Kuželički N, Mencej-Bedrač S, Jazbec J, Marc J, Mlinarič-Raščan I.

Exp Ther Med. 2016 Aug;12(2):840-846. Epub 2016 May 25.

14.

Structural requirements of acylated Gly-l-Ala-d-Glu analogs for activation of the innate immune receptor NOD2.

Gobec M, Mlinarič-Raščan I, Dolenc MS, Jakopin Ž.

Eur J Med Chem. 2016 Jun 30;116:1-12. doi: 10.1016/j.ejmech.2016.03.030. Epub 2016 Mar 16.

PMID:
27039337
15.

Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5 i) Subunit of the Immunoproteasome.

Sosič I, Gobec M, Brus B, Knez D, Živec M, Konc J, Lešnik S, Ogrizek M, Obreza A, Žigon D, Janežič D, Mlinarič-Raščan I, Gobec S.

Angew Chem Int Ed Engl. 2016 May 4;55(19):5745-8. doi: 10.1002/anie.201600190. Epub 2016 Apr 1.

PMID:
27037901
16.

Structure-Activity Relationships of Novel Tryptamine-Based Inhibitors of Bacterial Transglycosylase.

Sosič I, Anderluh M, Sova M, Gobec M, Mlinarič Raščan I, Derouaux A, Amoroso A, Terrak M, Breukink E, Gobec S.

J Med Chem. 2015 Dec 24;58(24):9712-21. doi: 10.1021/acs.jmedchem.5b01482. Epub 2015 Dec 3.

PMID:
26588190
17.

Antioxidant and anti-inflammatory properties of 1,2,4-oxadiazole analogs of resveratrol.

Gobec M, Tomašič T, Markovič T, Mlinarič-Raščan I, Dolenc MS, Jakopin Ž.

Chem Biol Interact. 2015 Oct 5;240:200-7. doi: 10.1016/j.cbi.2015.08.018. Epub 2015 Aug 31.

PMID:
26335192
18.

Oxidatively altered IgG with increased immunoreactivity to β2-glycoprotein I and its peptide clusters influence human coronary artery endothelial cells.

Artenjak A, Omersel J, Ahlin Grabnar P, Mlinarič-Raščan I, Shoenfeld Y, Sodin-Semrl S, Božič B, Čučnik S.

Lupus. 2015 Apr;24(4-5):448-62. doi: 10.1177/0961203314561073.

PMID:
25801888
19.

Characterization of human lymphoblastoid cell lines as a novel in vitro test system to predict the immunotoxicity of xenobiotics.

Markovič T, Gobec M, Gurwitz D, Mlinarič-Raščan I.

Toxicol Lett. 2015 Feb 17;233(1):8-15. doi: 10.1016/j.toxlet.2014.12.013. Epub 2014 Dec 24.

PMID:
25542143
20.

Discovery of novel small-molecule compounds with selective cytotoxicity for Burkitt's lymphoma cells using 3D ligand-based virtual screening.

Gobec M, Sosič I, Brus B, Obreza A, Gobec S, Mlinarič-Raščan I.

Molecules. 2014 Nov 19;19(11):19209-19. doi: 10.3390/molecules191119209.

21.

Association of ITPA genotype with event-free survival and relapse rates in children with acute lymphoblastic leukemia undergoing maintenance therapy.

Smid A, Karas-Kuzelicki N, Milek M, Jazbec J, Mlinaric-Rascan I.

PLoS One. 2014 Oct 10;9(10):e109551. doi: 10.1371/journal.pone.0109551. eCollection 2014.

22.

From pharmacogenetics to pharmacometabolomics: SAM modulates TPMT activity.

Karas-Kuželički N, Šmid A, Tamm R, Metspalu A, Mlinarič-Raščan I.

Pharmacogenomics. 2014 Aug;15(11):1437-49. doi: 10.2217/pgs.14.84.

23.

Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment.

Švajger U, Gobec M, Obreza A, Mlinarič-Raščan I.

Cancer Immunol Immunother. 2015 Jan;64(1):15-27. doi: 10.1007/s00262-014-1608-x. Epub 2014 Sep 25.

PMID:
25253531
24.

Chemo-sensitizing effects of EP4 receptor-induced inactivation of nuclear factor-κB.

Gobec M, Prijatelj M, Delić J, Markovič T, Mlinarič-Raščan I.

Eur J Pharmacol. 2014 Nov 5;742:81-8. doi: 10.1016/j.ejphar.2014.08.039. Epub 2014 Sep 9.

PMID:
25218986
25.

Screening of bisphenol A, triclosan and paraben analogues as modulators of the glucocorticoid and androgen receptor activities.

Kolšek K, Gobec M, Mlinarič Raščan I, Sollner Dolenc M.

Toxicol In Vitro. 2015 Feb;29(1):8-15. doi: 10.1016/j.tiv.2014.08.009. Epub 2014 Sep 2.

PMID:
25192815
26.

Structural characterization and biological evaluation of a clioquinol-ruthenium complex with copper-independent antileukaemic activity.

Gobec M, Kljun J, Sosič I, Mlinarič-Raščan I, Uršič M, Gobec S, Turel I.

Dalton Trans. 2014 Jun 28;43(24):9045-51. doi: 10.1039/c4dt00463a.

PMID:
24781711
27.

Molecular docking revealed potential disruptors of glucocorticoid receptor-dependent reporter gene expression.

Kolšek K, Gobec M, Mlinarič Raščan I, Sollner Dolenc M.

Toxicol Lett. 2014 Apr 21;226(2):132-9. doi: 10.1016/j.toxlet.2014.01.047. Epub 2014 Feb 8.

PMID:
24518828
28.

Synthesis of conformationally constrained γ-D-glutamyl-meso-diaminopimelic acid derivatives as ligands of nucleotide-binding oligomerization domain protein 1 (Nod1).

Jakopin Ž, Gobec M, Kodela J, Hazdovac T, Mlinarič-Raščan I, Sollner Dolenc M.

Eur J Med Chem. 2013 Nov;69:232-43. doi: 10.1016/j.ejmech.2013.08.022. Epub 2013 Aug 30.

PMID:
24044936
29.

Cinnamic acid derivatives induce cell cycle arrest in carcinoma cell lines.

Sova M, Žižak Ž, Stanković JA, Prijatelj M, Turk S, Juranić ZD, Mlinarič-Raščan I, Gobec S.

Med Chem. 2013 Aug;9(5):633-41.

PMID:
23140579
30.

Selective cytotoxicity of amidinopiperidine based compounds towards Burkitt's lymphoma cells involves proteasome inhibition.

Gobec M, Obreza A, Prijatelj M, Brus B, Gobec S, Mlinaric-Rascan I.

PLoS One. 2012;7(7):e41961. doi: 10.1371/journal.pone.0041961. Epub 2012 Jul 30.

31.

EP4 receptor signalling in immature B cells involves cAMP and NF-κB dependent pathways.

Prijatelj M, Celhar T, Gobec M, Mlinaric-Rascan I.

J Pharm Pharmacol. 2012 Aug;64(8):1090-8. doi: 10.1111/j.2042-7158.2012.01499.x. Epub 2012 Mar 22.

PMID:
22775212
32.

Immunomodulatory properties of novel nucleotide oligomerization domain 2 (nod2) agonistic desmuramyldipeptides.

Jakopin Ž, Gobec M, Mlinarič-Raščan I, Sollner Dolenc M.

J Med Chem. 2012 Jul 26;55(14):6478-88. doi: 10.1021/jm300503b. Epub 2012 Jul 5.

PMID:
22716113
33.

Post-translational stabilization of thiopurine S-methyltransferase by S-adenosyl-L-methionine reveals regulation of TPMT*1 and *3C allozymes.

Milek M, Smid A, Tamm R, Kuzelicki NK, Metspalu A, Mlinaric-Rascan I.

Biochem Pharmacol. 2012 Apr 1;83(7):969-76. doi: 10.1016/j.bcp.2012.01.010. Epub 2012 Jan 17.

PMID:
22274639
34.

Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs.

Jakopin Ž, Corsini E, Gobec M, Mlinarič-Raščan I, Dolenc MS.

Eur J Med Chem. 2011 Sep;46(9):3762-77. doi: 10.1016/j.ejmech.2011.05.042. Epub 2011 May 27.

PMID:
21669478
35.

Prostaglandin EP4 receptor enhances BCR-induced apoptosis of immature B cells.

Prijatelj M, Celhar T, Mlinaric-Rascan I.

Prostaglandins Other Lipid Mediat. 2011 Aug;95(1-4):19-26. doi: 10.1016/j.prostaglandins.2011.04.001. Epub 2011 May 10.

PMID:
21600299
36.

Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood.

Rajić V, Aplenc R, Debeljak M, Prestor VV, Karas-Kuzelicki N, Mlinaric-Rascan I, Jazbec J.

Leuk Lymphoma. 2009 Oct;50(10):1693-8.

PMID:
19863340
37.

MTHFR and TYMS genotypes influence TPMT activity and its differential modulation in males and females.

Karas-Kuzelicki N, Milek M, Mlinaric-Rascan I.

Clin Biochem. 2010 Jan;43(1-2):37-42. doi: 10.1016/j.clinbiochem.2009.09.003. Epub 2009 Sep 11.

PMID:
19748501
38.

Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.

Karas-Kuzelicki N, Mlinaric-Rascan I.

Pharmacogenomics. 2009 Aug;10(8):1309-22. doi: 10.2217/pgs.09.78. Review.

PMID:
19663675
39.

A Myc-regulated transcriptional network controls B-cell fate in response to BCR triggering.

Murn J, Mlinaric-Rascan I, Vaigot P, Alibert O, Frouin V, Gidrol X.

BMC Genomics. 2009 Jul 17;10:323. doi: 10.1186/1471-2164-10-323.

40.

S-adenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts.

Milek M, Karas Kuzelicki N, Smid A, Mlinaric-Rascan I.

Biochem Pharmacol. 2009 Jun 15;77(12):1845-53. doi: 10.1016/j.bcp.2009.03.006. Epub 2009 Mar 19.

PMID:
19428339
41.

5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL).

Karas Kuzelicki N, Milek M, Jazbec J, Mlinaric-Rascan I.

Leuk Res. 2009 Oct;33(10):1344-8. doi: 10.1016/j.leukres.2008.12.011.

PMID:
19178944
42.

Azaphenylalanine-based serine protease inhibitors induce caspase-mediated apoptosis.

Celhar T, Batista Napotnik T, Obreza A, Zega A, Anderluh PS, Kikelj D, Mlinaric-Rascan I.

Eur J Pharmacol. 2009 Jan 5;602(1):15-22. doi: 10.1016/j.ejphar.2008.11.008. Epub 2008 Nov 12.

PMID:
19032950
43.

The presence of the CYP11A1 (TTTTA)6 allele increases the risk of biochemical relapse in organ confined and low-grade prostate cancer.

Celhar T, Gersak K, Ovcak Z, Sedmak B, Mlinaric-Rascan I.

Cancer Genet Cytogenet. 2008 Nov;187(1):28-33. doi: 10.1016/j.cancergencyto.2008.08.003.

PMID:
18992638
44.

Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients.

Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I.

Leukemia. 2009 May;23(5):971-4. doi: 10.1038/leu.2008.317. Epub 2008 Nov 6. No abstract available.

PMID:
18987660
45.

99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience.

Gmeiner Stopar T, Fettich J, Zver S, Mlinaric-Rascan I, Hojker S, Socan A, Peitl PK, Mather S.

Nucl Med Commun. 2008 Dec;29(12):1059-65. doi: 10.1097/MNM.0b013e3283134d6e.

PMID:
18987526
46.

Surface active stabilizer tyloxapol in colloidal dispersions exerts cytostatic effects and apoptotic dismissal of cells.

Kristl J, Teskac K, Milek M, Mlinaric-Rascan I.

Toxicol Appl Pharmacol. 2008 Oct 15;232(2):218-25. doi: 10.1016/j.taap.2008.06.019. Epub 2008 Jul 8.

PMID:
18657561
47.

A novel gene delivery system for stable transfection of thiopurine-S-methyltransferase gene in versatile cell types.

Egle R, Milek M, Mlinaric-Rascan I, Fahr A, Kristl J.

Eur J Pharm Biopharm. 2008 May;69(1):23-30. Epub 2007 Oct 11.

PMID:
17988843
48.

Thiopurine S-methyltransferase pharmacogenetics: genotype to phenotype correlation in the Slovenian population.

Milek M, Murn J, Jaksic Z, Lukac Bajalo J, Jazbec J, Mlinaric Rascan I.

Pharmacology. 2006;77(3):105-14. Epub 2006 May 10.

PMID:
16691038
49.

(99m)Tc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent.

Stopar TG, Mlinaric-Rascan I, Fettich J, Hojker S, Mather SJ.

Eur J Nucl Med Mol Imaging. 2006 Jan;33(1):53-9. Epub 2005 Sep 20.

PMID:
16172899
50.

Internucleosomal DNA cleavage in apoptotic WEHI 231 cells is mediated by a chymotrypsin-like protease.

Murn J, Urleb U, Mlinaric-Rascan I.

Genes Cells. 2004 Nov;9(11):1103-11.

Supplemental Content

Loading ...
Support Center